Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Diluted Average) (2017 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Shares Outstanding (Diluted Average) for 12 consecutive years, with $140.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 12.7% year-over-year to $140.7 million, compared with a TTM value of $140.7 million through Dec 2025, up 12.7%, and an annual FY2025 reading of $133.8 million, up 11.67% over the prior year.
  • Shares Outstanding (Diluted Average) was $140.7 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $133.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $140.7 million in Q4 2025 and bottomed at $103.3 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $115.1 million, with a median of $107.2 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) rose 1.26% in 2023, then rose 16.23% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $104.5 million in 2021, then grew by 1.44% to $106.0 million in 2022, then increased by 1.3% to $107.4 million in 2023, then rose by 16.23% to $124.8 million in 2024, then increased by 12.7% to $140.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for ARWR at $140.7 million in Q4 2025, $133.8 million in Q3 2025, and $139.0 million in Q2 2025.